Deutsche Bank analyst Pito Chickering lowered the firm’s price target on Universal Health (UHS) to $203 from $208 and keeps a Buy rating on the shares. The stock’s fiscal 2024 EBITDA multiple is a touch below the ten-year average, a 2025 price-to-earnings multiple at a 39% discount to the S&P 500 Index, and a multiple delta versus HCA (HCA) right around multi-year highs, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UHS:
- Universal Health falls after subsidiary hit with $535M jury verdict
- Universal Health price target raised to $185 from $175 at Stephens
- Universal Health Sets 2024 Executive Incentive Bonuses
- Universal Health price target raised to $183 from $161 at RBC Capital
- Universal Health price target raised to $200 from $175 at Mizuho